These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23055216)

  • 1. Photodynamic therapy for pancreatic and biliary tract cancer: the United Kingdom experience.
    Pereira S
    J Natl Compr Canc Netw; 2012 Oct; 10 Suppl 2():S48-51. PubMed ID: 23055216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).
    Okusaka T; Ueno M; Sato T; Heike Y
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):314-8. PubMed ID: 22273718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of chemotherapy in treatments for biliary tract cancer.
    Furuse J; Kasuga A; Takasu A; Kitamura H; Nagashima F
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):337-41. PubMed ID: 22456744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
    Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
    Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
    Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
    Lee KJ; Yi SW; Cha J; Seong J; Bang S; Song SY; Kim HM; Park SW
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):841-6. PubMed ID: 27586966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
    Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
    Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
    Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.
    Wilkowski R; Thoma M; Schauer R; Wagner A; Heinemann V
    World J Surg; 2004 Oct; 28(10):1011-8. PubMed ID: 15573257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas].
    Bokemeyer C; Kollmannsberger C; Oettle H; Kanz L
    Praxis (Bern 1994); 2000 Sep; 89(39):1545-52. PubMed ID: 11068508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
    Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW
    Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
    Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
    Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant treatments for biliary tract cancer.
    Furuse J
    J Hepatobiliary Pancreat Surg; 2008; 15(5):463-7. PubMed ID: 18836797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
    Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
    Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
    Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
    Woo SM; Lee WJ; Kim JH; Kim DH; Han SS; Park SJ; Kim TH; Lee JH; Koh YH; Hong EK
    Chemotherapy; 2013; 59(3):232-8. PubMed ID: 24356333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
    Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
    Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.